Pharmacological therapeutic prospects of cerebral vasospasm;LES PERSPECTIVES THERAPEUTIQUES PHARMACOLOGIQUES DU VASOSPASME CEREBRAL

Annales Francaises d'Anesthesie et de Reanimation

Volumn 15, Issue 3, 1996, Pages 374-381

  Hans, P ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

subarachnoid haemorrhage; treatment; vasospasm

Indexed keywords

8 TERT BUTYL 6,7 DIHYDRO 5 METHYLPYRROLO[3,2 E]PYRAZOLO[1,5 A]PYRIMIDINE 3 CARBONITRILE; CYCLOPIAZONIC ACID; FIBRINOLYTIC AGENT; NAFAMSTAT MESILATE; PROTEIN KINASE C INHIBITOR; SUPEROXIDE DISMUTASE; TIRILAZAD; TISSUE PLASMINOGEN ACTIVATOR; ANTIOXIDANT; LIPID PEROXIDE; OXYHEMOGLOBIN; PLASMINOGEN ACTIVATOR; PREGNANE DERIVATIVE;

BRAIN ARTERY ANEURYSM RUPTURE; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; FIBRINOLYSIS; LIPID PEROXIDATION; SUBARACHNOID HEMORRHAGE; TREATMENT OUTCOME; VASOSPASM; ARTICLE; DRUG ANTAGONISM; HUMAN; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; METABOLISM; PATHOPHYSIOLOGY; TRANSIENT ISCHEMIC ATTACK;

ANTIOXIDANTS; FIBRINOLYSIS; HUMANS; INJECTIONS, INTRAVENTRICULAR; ISCHEMIC ATTACK, TRANSIENT; LIPID PEROXIDES; OXYHEMOGLOBINS; PLASMINOGEN ACTIVATORS; PREGNATRIENES; SUBARACHNOID HEMORRHAGE; SUPEROXIDE DISMUTASE;

EID: 0029891511     PISSN: 07507658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0750-7658(96)80022-0     Document Type: Conference Paper

References (50)

1. Fischer CM, Kistler JP, Davis JM, Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery 1980;6:1-9
2. Findlay JM, McDonald RL, Weir BKA. Current concepts of pathophysiology and management of cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Cereb Brain Metab Rev 1991;3:336-61
3. Foley PL, Takenaka K, Kassell NF, Lee KS. Cytotoxic effects of bloody cerebrospinal fluid on cerebral endothelial cells in culture. J Neurosurg 1994;81:87-92
4. Duff TA, Louie J, Feilbach JA, Scott G, Erythrocytes are essential for development of cerebral vasculopathy resulting from subarachnoid hemorrhage in cats. Stroke 1988;19:68-72
5. Peterson JW, Roussos L, Kwun BD, Hackett JD, Owen CJ, Zervas NT. Evidence of the role of hemolysis in experimental cerebral vasospasm. J Neurosurg 1990;72:775-81
6. Foley PL, Kassell NF, Hudson SB, Lee KS. Hemoglobin penetration in the wall of the rabbit basilar artery after subarachnoid hemorrhage and intracisternal hemoglobin injection. Acta Neurochirurg 1993;123:82-6
7. Aoki T, Takenaka K, Suzuki S, Kassel NF, Sagher D, Lee KS. The role of hemolysate in the facilitation of oxyhemoglobin-induced contraction in rabbit basilar arteries. J Neurosurg 1994;81:261-6
8. Findlay JM, Weir BKA, Gordon P, Grace M, Baughman R. Safety and efficacy of intrathecal thrombolytic therapy in a primate model of cerebral vasospasm. Neurosurg 1989;24:491-8
9. Mizoi K, Yoshimoto T, Fujiwara S, Sugawara T, Takahashi A, Koshu K. Prevention of vasospasm by clot removal and intrathecal bolus injection of tissue-type plasminogen activator: preliminary report. Neurosurg 1991;28:807-3
10. Zabramski JM, Spetzler RF, Lee KS, Papadopoulos SM, Bovill E, Zimmerman RS et al. Phase 1 trial of tissue plaminogen activator for the prevention of vasospasm in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg 1991;75:189-96
11. Stolke D, Seifert V. Single intracisternal bolus of recombinant tissue plasminogen activator in patients with aneurysmal subarachnoid hemorrhage: preliminary assessment of efficacy and safety in an open clinical study. Neurosurg 1992;30:877-81
12. Findlay JM, Weir BKA, Grace MGA. Intracisternal recombinant tissue plasminogen activator after aneurysmal subarachnoid hemorrhage: results of preliminary study. In: Pasqualin A, Da Pian R, eds. New trends in management of cerebro-vascular malformations. Wien, New-York: Springer-Verlag 1992;121-4
13. Zabramski JM, Spetzler RF, Papadopoulos SM, Bovill T. Intracisternal therapy with tissue plasminogen activator for the prevention of vasospasm in patients with aneurysmal subarachnoid hemorrhage. A review. In: Pasqualin A, Da Pian R, eds. New trends in management of cerebro-vascular malformations. Wien, New York: Springer-Verlag, 1992:125-31
14. Mizoi K, Yoshimoto T, Takahashi A, Koshu K, Sugawara T. Prospective study on the prevention of cerebral vasospasm by intrathecal fibrinolysis therapy with tissue-type plasminogen activator. J Neurosurg 1993,78:430-37
15. Asada M, Kong J, Nakamura M, Ehara K, Fujita K, Tamaki N. Combination therapy with tissue plasminogen activator and antithrombin III in experimental vasospasm. In: FIindlay JM, ed. Developments in neurology: cerebral vasospasm. Amsterdam: Elsevier Science Publishers, 1993:487-90
16. Sasaki S, Ohta S, Nakamura H, Takeda S. Free radical reaction and biological defense mechanism in the pathogenesis of prolonged vasospasm in experimental subarachnoid hemorrhage. J Cereb Blood Flow Metab 1988;8:1-8
17. Takenaka K, Kassel NF, Foley PL, Lee KS. Oxyhemoglobin-induced cytotoxicity and arachidonic acid release in cultured bovine endothelial cells. Stroke 1993;24:839-46
18. McDonald RL, Weir BKA, Runzer TD, Grace MGA, Poznanski MJ. Effect of intrathecal superoxide dismutase and catalase on oxyhemoglobin-induced vasospasm in monkeys. Neurosurg 199;30:529-39
19. Shishido T, Suzuki R, Qian L, Hirakawa K. The role of superoxide anion in the pathogenesis of cerebral vasospasm. Stroke 1994;25:864-8
20. Harada T, Mayberg MR. Inhibition of delayed arterial narrowing by the iron-chelating agent deferoxamine. J Neurosurg 1922;77:763-7
21. Harada T, Luo S, London S, Gajdusek C, Mayberg M. Antioxidant and iron-chelating agents in cerebral vasospasm. In: FIindlay JM, ed. Developments in neurology: cerebral vasospasm. Amsterdam: Elsevier Science Publishers, 1993:171-4
22. Matsui T, Asano T. Effects of new 21-aminosteroid tirilazad mesylate (U74006F) on chronic cerebral vasospasm in a « two-hemorrhage » model of beagle dogs. Neurosurg 1994;34:1035-9
23. Haley EC, Kassell NF, Alves WM, Weir BKA, Hansen CA. Phase II trial of tirilazad in aneurysmal subarachnoid hemorrhage: a report of the cooperative aneurysm study. J Neurosurg 1995;82:786-90
24. Smith DH, Gennarelli TA, McIntosh T. The potential of 21-aminosteroids (lazaroids) as neuroprotective therapies in CNS injuries, CNS Drugs 1995;3:159-64
25. Takahashi S, Kassel NF, Takenaka K, Aoki T, Lee KS. Effects of the dual action compounds, U92032 and U92798 on experimental cerebral vasospasm in rabbit. In: FIindlay JM, ed. Developments in neurology: cerebral vasospasm. Amsterdam: Elsevier Science Publishers, 1993:421-5
26. Takahashi S, Kassel NF, Toshima M, Dougherty DA, Foley PL, Lee KS, Effect of U88999E on experimental cerebral vasospasm in rabbits. Neurosurg 1993;32:281-8
27. McDonald RL, Weir BK. Cerebral vasospasm and free radicals. Free Radical Biol Med 1994;16:633-43
28. Connor HE, Feniuk W. The role of endothelium in haemoglobin-induced contraction of dog basilar artery. Eur J Pharmacol 1987;140:105-8
29. Tsuji T, Weir BKA, Cook DA. Time-dependent effects of extraluminally-applied oxyhemoglobin and endothelial removal on vasodilator responses in isolated, perfused canine basilar arteries. Pharmacology 1989;38:101-12
30. Kasuya H, Weir BK, White DM, Stefanson K. Mechanism of oxyhemoglobin-induced release of endothelin-1 from cultured vascular endothelial cells and smooth-muscle cell. J Neurosurg 1993;79:892-8
31. Suzuki R, Masaoka H, Hirata Y, Marumo F, Isotani E, Hirakawa K. The role of endothelin-1 in the origin of cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg 1992;77:96-100
32. Suzuki R, Masaoka H, Hirata Y, Marumo F, Isotani E, Hirakawa K. The role of endothelin-1 in the origin of cerebral vasospasm. In: Findlay JM, ed. Developments in neurology: cerebral vasospasm. Amsterdam: Elsevier Science Publishers, 1993:205-8
33. Sasaki T. Possible participation of endothelin-1 in the genesis of vasospasm. In: Findlay JM, ed. Developments in neurology: cerebral vasospasm. Amsterdam: Elsevier Science Publishers, 1993:221-4
34. Foley PL, Caner HH, Kassell NF, Lee KS. Reversal of subarachnoid hemorrhage-induced vasoconstriction using an endothelin receptor antagonist. Neurosurg 1994;34:108-12
35. Vollrath BA, Weir BK, McDonald RL, Cook DA. Intracellular mechanisms involved in the responses of cerebrovascular smoothmuscle cells to hemoglobin. J Neurosurg 1994;80:261-8
36. Zhang H, Inazu M, Daniel EE, Weir B. Activation of protein kinase C inhibits potassium channels in cultured endothelial cells. In: Findlay JM, ed. Developments in neurology: cerebral vasospasm. Amsterdam: Elsevier Science Publishers, 1993:133-36
37. Cook DA, Luong T, Doi M, Vollrath B. Prolonged activation of protein kinase C in oxyhaemoglobin-induced vasoconstriction in canine basilar artery. In: Findlay JM, ed. Developments in neurology: cerebral vasospasm. Amsterdam: Elsevier Science Publishers, 1993:125-8
38. Bell BA. Effect of calcitonin gene-related peptide on outcome of ischaemic deficits after subarachnoid hemorrhage. In: Pasqualin A, Da Pian R, eds. European CGRP group in subarachnoid haemorrhage study group. New York: Springer Verlag, 1992:102-6
39. 2+ influx through non-specific channels in endothelial cell. Eur J Pharmacol 1994;251:119-25
40. Inazu M, Zhang H, Weir B, Daniel EE. Effect of LP-805, a releaser of endothelium-derived nitric oxide, on ion channels in cultured endothelial cells. In: Findlay JM, ed. Developments in neurology: cerebral vasospasm. Amsterdam: Elsevier Science Publishers, 1993: 243-6
41. Suzuki Y, Kajita Y, Oyama H, Tanazawa T, Takayasa M, Shikuya M et al. Dysfunction of nitric oxide in the spastic basilar arteries after subarachnoid hemorrhage. J Autonom Nerv Syst 1994;49:S83-7
42. Kasuya H, Weir BK, Nakane M, Pollock JS, Johns L, Marton LS et al. Nitric oxide synthase and guanylate cyclase levels in canine basilar artery after subarachnoid hemorrhage. J Neurosurg 1995;82:250-5
43. Kajita Y, Suzuki Y, Oyama H, Tanazawa T, Takayasu M, Shibuya M et al. Combined effect of L-arginine and superoxide dismutase on the spastic basilar artery after subarachnoid hemorrhage in dogs. J Neurosurg 1994;80:476-83
44. Takayasu M, Kajita Y, Suzuki Y, Mori Y, SHibuya M, Sujita K et al. Oxyhemoglobin enhancement of vasopressin-induced constriction in rat cerebral arterioles. Life Sci 1994,56:123-7
45. Peterson JW, Kwun BD, Hacket JD, Zewas NT. The role of inflammation in experimental cerebral vasospasm. J Neurosurg 1990;72:767-74
46. Kasuya H, Shimizu T. Activated complement components C3a and C4a in cerebrospinal fluid and plasma following subarachnoid hemorrhage. J Neurosurg 1989;71:741-6
47. Yanamoto H, Kikuchi H, Ishikawa J, Shimizu Y, Sato M, Tokuriki Y et al. Intravenous FUT-175 inhibits complement activation in the cerebrospinal fluid and vasospasm related delayed ischemia neurological deficit following subarachnoid hemorrhage. In: Findlay JM, ed, Developments in neurology: cerebral vasospasm. Amsterdam: Elsevier Science Publishers, 1993:431-4
48. Yanamoto H, Kikuchi H, Okamoto S, Nozaki K. Cerebral vasospasm caused by cisternal injection of polystyrene latex beads in rabbits is inhibited by a serine protease inhibitor. Surg Neurol 1994;42:374-381
49. Yanamoto H, Kikuchi H, Okamoto S. Effects of protease inhibitor and immunesuppressant on cerebral vasospasm after subarachnoid hemorrhage in rabbits. Surg Neurol 1994;42:382-7
50. Yanamoto H, Kikuchi H, Sato M, Shimizu Y, Yoneda S, Okamoto S. Therapeutic trial of cerebral vasospasm with the serine protease inhibitor, FUT-175, administered in the acute stage after subarachnoid hemorrhage. Neurosurg 1992;30:358-363